Brief: Inflarx’s Gohibic Selected For First BARDA-Sponsored Clinical Trial To Evaluate Novel Host-Directed Therapeutics For Acute Respiratory Distress Syndrome
24/06/2024 15:29
June 24 (Reuters) - InflaRx NV IF0G.F :
* INFLARX’S GOHIBIC (VILOBELIMAB) SELECTED FOR FIRST
BARDA-SPONSORED CLINICAL TRIAL TO EVALUATE NOVEL HOST-DIRECTED
THERAPEUTICS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
* INFLARX NV - INFLARX'S GOHIBIC SELECTED BY BARDA FOR ARDS
STUDY
Source text for Eikon: ID:nGNX4H2JSh
Further company coverage: IF0G.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum